GlassScriptPhysician profile
Jawad Riaz
NPI 1962425280
$4,708.86
in general payments reported to CMS, 2019-2025
29 companies · $671 in 2025
The $671 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $741 · 2021: $982 · 2022: $554 · 2023: $509 · 2024: $311 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.37 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.40 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $685.73 | 2019-2022 | |
| Allergan, INC. | $485.09 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $437.16 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $353.84 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $294.55 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.14 | 2020-2025 | Caplyta |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $160.13 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $139.97 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.11 | 2020-2021 | |
| Indivior INC. | $88.06 | 2019-2023 | Sublocade |
| Axsome Therapeutics, INC. | $66.31 | 2023-2025 | Auvelity, Sunosi |
| Avanir Pharmaceuticals, INC. | $58.77 | 2021 | |
| Ironshore Pharmaceuticals INC. | $50.69 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.51 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $44.77 | 2019 | |
| Almatica Pharma LLC | $42.00 | 2022-2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $39.23 | 2025 | |
| Eisai INC. | $34.73 | 2020 | |
| Idorsia Pharmaceuticals US INC | $27.30 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $22.46 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $22.46 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $20.17 | 2024 | Xelstrym |
| Tris Pharma INC | $18.68 | 2025 | Dyanavel Xr |
| Harmony Biosciences LLC | $18.15 | 2023 | Wakix |
| Bausch Health US, LLC | $16.35 | 2022 | |
| Corium, LLC | $16.10 | 2024 | Azstarys |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.